ClinConnect ClinConnect Logo
Search / Trial NCT06230640

Evaluation of TEG 6S PM® During Cardiopulmonary Bypass to Detect Postoperative Biological Coagulopathy

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Jan 29, 2024

Trial Information

Current as of July 06, 2025

Completed

Keywords

Coagulopathy Cardiac Surgery Cardiopulmonary Bypass

ClinConnect Summary

This clinical trial is looking at a special test called TEG 6S platelet mapping® to see if it can help predict bleeding problems after certain types of heart surgery. When patients undergo cardiac surgery, especially those that require a machine to help pump blood (known as cardiopulmonary bypass), there is a risk of complications related to blood clotting. The researchers want to find out if this test can provide valuable information to help manage those risks and ensure better outcomes for patients.

To be eligible for this trial, participants need to be at least 18 years old and scheduled for heart surgery that has a high chance of bleeding, such as heart transplants or surgeries that last over two hours on the bypass machine. However, some people won't be able to participate, like those with specific allergies to blood thinners or those currently involved in other studies. If you decide to join the study, you can expect to undergo the TEG 6S test during your surgery, which aims to improve care and safety for patients like you. Your participation could help advance medical knowledge and improve future treatments for others.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years old or older
  • * Cardiac surgery under cardiopulmonary bypass with high risk of bleeding defined among:
  • CPB with circulatory arrest
  • cardiac transplantation
  • Redo surgery
  • infective endocarditis
  • predicted duration of CBP ≥ 120 min
  • High transfusion risk defined by a Trust predictive score ≥ 3 (Transfusion Risk Understanding Scoring Tool)
  • Exclusion Criteria:
  • Patient with heparin allergy or heparin-induced thrombocytopenia
  • Use of direct oral anticoagulant (DAA) with anti-factor X activity (Apixaban, Rivaroxaban) \< 72h, even if antagonized
  • Patient on partially or fully antagonized VKAs
  • Opposition to participation after a period of reflection
  • Adult protected by law (guardianship, curatorship)
  • Person deprived of liberty
  • Person participating in another study with an exclusion period still in progress
  • Patient not affiliated to a social security scheme or not benefiting from such a scheme
  • Pregnant or breast-feeding woman

About University Hospital, Montpellier

The University Hospital of Montpellier is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. Renowned for its commitment to patient-centered care, the hospital collaborates with multidisciplinary teams to explore cutting-edge treatments and therapies across various medical fields. By integrating clinical practice with education and research, the University Hospital of Montpellier aims to enhance health outcomes and contribute to the scientific community's understanding of complex medical conditions. Its robust infrastructure and expertise make it a pivotal player in the landscape of clinical research.

Locations

Montpellier, , France

Patients applied

0 patients applied

Trial Officials

Benjamin Bourdois, MD

Study Director

University Hospital, Montpellier

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported